Sihuan Pharmaceutical Holdings Group Ltd
Company Profile
Business description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
Contact
Zhubang 2000
22nd Floor, Building 4
West Balizhuang, Chaoyang District
Beijing100025
CHNT: +86 1057693700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,767
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 42.50 | 0.46% |
| CAC 40 | 8,313.12 | 17.84 | -0.21% |
| DAX 40 | 25,352.39 | 66.15 | 0.26% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,238.94 | 54.59 | 0.54% |
| HKSE | 26,766.20 | 157.42 | -0.58% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,903.90 | 42.20 | 0.48% |
| SSE Composite Index | 4,100.48 | 12.12 | -0.29% |